ABOS
Income statement / Annual
Last year (2024), Acumen Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Acumen Pharmaceuticals, Inc.'s net income was -$102.33 M.
See Acumen Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.44 M |
$1.70 M |
| Cost of Revenue |
$0.00
|
$42.32 M
|
$169.00 K
|
$4.00 K
|
$8.00 K
|
$8.58 K
|
| Gross Profit |
$0.00
|
-$42.32 M
|
-$169.00 K
|
-$4.00 K
|
$1.43 M
|
$1.69 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0.99
|
0.99
|
| Research and Development Expenses |
$93.80 M
|
$42.32 M
|
$32.36 M
|
$12.31 M
|
$8.00 M
|
$8.58 M
|
| General & Administrative Expenses |
$20.22 M
|
$18.82 M
|
$12.88 M
|
$7.28 M
|
$1.35 M
|
$926.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$20.22 M
|
$18.82 M
|
$12.88 M
|
$7.28 M
|
$1.35 M
|
$926.00 K
|
| Other Expenses |
$0.00
|
-$42.32 M
|
-$11.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$114.02 M
|
$61.14 M
|
$12.88 M
|
$19.58 M
|
$7.91 M
|
$9.50 M
|
| Cost And Expenses |
$114.02 M
|
$61.14 M
|
$45.24 M
|
$19.58 M
|
$9.35 M
|
$9.50 M
|
| Interest Income |
$14.32 M
|
$10.79 M
|
$2.39 M
|
$84.00 K
|
$1.00 K
|
$45.00 K
|
| Interest Expense |
$4.07 M
|
$581.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$178.00 K
|
$184.00 K
|
$169.00 K
|
$4.00 K
|
$0.00
|
$7.81 M
|
| EBITDA |
-$98.08 M |
-$51.61 M |
-$42.69 M |
-$19.58 M |
-$7.91 M |
$119.00 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-5.51
|
0.07
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-5.51
|
-4.6
|
| Total Other Income/Expenses Net |
$11.69 M
|
$8.77 M
|
$2.38 M
|
-$81.02 M
|
$587.00 K
|
-$102.00 K
|
| Income Before Tax |
-$102.33 M
|
-$52.37 M
|
-$42.86 M
|
-$100.61 M
|
-$7.33 M
|
-$7.91 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-5.1
|
-4.66
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$45.00 K
|
| Net Income |
-$102.33 M
|
-$52.37 M
|
-$42.86 M
|
-$100.61 M
|
-$7.33 M
|
-$7.86 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-5.1
|
-4.63
|
| EPS |
-1.71 |
-1.08 |
-1.06 |
-2.63 |
-0.26 |
-0.2 |
| EPS Diluted |
-1.71 |
-1.08 |
-1.06 |
-2.63 |
-0.26 |
-0.27 |
| Weighted Average Shares Out |
$60.01 M
|
$48.49 M
|
$40.60 M
|
$38.27 M
|
$28.65 M
|
$28.65 M
|
| Weighted Average Shares Out Diluted |
$60.01 M
|
$48.61 M
|
$40.60 M
|
$38.27 M
|
$28.65 M
|
$28.65 M
|
| Link |
|
|
|
|
|
|
